Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized Private Offering of $625 Million of Convertible Senior Notes

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a leader in converting IV biologics to subcutaneous delivery, has announced the pricing of $625.0 million aggregate principal amount of convertible senior notes due 2028. The Convertible Notes are being offered and sold to "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933. The offering was upsized from an originally announced $500 million in aggregate principal amount. The Company also granted a 13-day option to the initial purchasers to purchase up to an additional $95.0 million aggregate principal amount of Convertible Notes.

Latham & Watkins LLP represents the initial purchasers in the offering with a corporate deal team led by San Diego partners Cheston Larson and Michael Sullivan, with associates Peter Simon, Rachel Staub, and Alex Stuart-Lovell. Advice was provided on convertible debt matters by New York/Los Angeles partner Greg Rodgers, with associates Andrew Blumenthal and Andrew Bentz; on regulatory matters by Washington, D.C. partner Ben Haas and Bay Area counsel Betty Pang, with associate Chad Jennings; on intellectual property matters by San Diego partner Steven Chinowsky and San Diego counsel Darryl Steensma, with associate Robert Yeh; on derivatives matters by New York partner Reza Mojtabaee-Zamani, with associates Jack Neff and Hera Liao; and on tax matters by New York partner Bora Bozkurt, with associate Ted Gkoo.